SHANGHAI and HONG KONG, Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmac...
AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration (FDA) has approved VYALEV™ (foscarbidopa and foslevodopa) as the first and o...
Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into ...
AstraZeneca will share new data across its Vaccines & Immune Therapies portfolio at the 13th annual IDWeek in Los Angeles, California, from 16-19 ...
Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been s...
LeaderMed Group (LeaderMed), a global pharmaceutical development company, and Combiphar, a leading Indonesian pharmaceutical company in Southeast Asia, ann...
The Oxford-Harrington Rare Disease Centre (‘OHC’), a partnership between the University of Oxford, UK and Harrington Discovery Institute at U...
Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a pro forma basis Adds two d...
Lilly Seaport Innovation Center (LSC) serves as the central hub for Lilly's genetic medicines efforts and houses the first East Coast Lilly Gateway Labs ...
Composition-of-matter patent covers the therapeutic use of arsenic salts and metal ions through various routes of administration. Enriched IP portfoli...
Agreement will see NewBridge Pharmaceuticals act as a multi-country distributor in four countries across the Middle East and North Africa (MENA) ...
Thermo Fisher Scientific Inc., the world leader in serving science, announced that its SeCore™ CDx HLA A Sequencing System has been granted 5...
NOVIO a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related disease...
Award supports preclinical research of Lario’s CaV2.3 calcium channel inhibitors as a novel disease-modifying approach for treatment of Par...
© 2025 Biopharma Boardroom. All Rights Reserved.
